X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with FINOLEX IND. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs FINOLEX IND. - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

FINOLEX IND. 
   Change

Established in 1981, Finolex Industries is the only integrated pipe manufacturer in India. It derives 72% of its earnings from the PVC business and the rest from pipes and fittings. The main demand for PVC comes from agricultural, housing, constructi... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES FINOLEX IND. INDOCO REMEDIES/
FINOLEX IND.
 
P/E (TTM) x 36.9 23.4 157.4% View Chart
P/BV x 2.9 9.5 30.2% View Chart
Dividend Yield % 0.8 1.2 68.2%  

Financials

 INDOCO REMEDIES   FINOLEX IND.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
FINOLEX IND.
Mar-14
INDOCO REMEDIES/
FINOLEX IND.
5-Yr Chart
Click to enlarge
High Rs360200 180.6%   
Low Rs24994 265.6%   
Sales per share (Unadj.) Rs119.0197.7 60.2%  
Earnings per share (Unadj.) Rs8.413.7 61.0%  
Cash flow per share (Unadj.) Rs15.218.7 81.3%  
Dividends per share (Unadj.) Rs1.607.00 22.9%  
Dividend yield (eoy) %0.54.8 11.0%  
Book value per share (Unadj.) Rs70.763.6 111.1%  
Shares outstanding (eoy) m92.15124.09 74.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.60.7 345.0%   
Avg P/E ratio x36.410.7 340.6%  
P/CF ratio (eoy) x20.07.8 255.5%  
Price / Book Value ratio x4.32.3 187.0%  
Dividend payout %19.151.1 37.5%   
Avg Mkt Cap Rs m28,08318,204 154.3%   
No. of employees `0006.01.1 546.7%   
Total wages/salary Rs m2,167717 302.1%   
Avg. sales/employee Rs Th1,817.022,219.5 8.2%   
Avg. wages/employee Rs Th359.0649.5 55.3%   
Avg. net profit/employee Rs Th127.71,541.2 8.3%   
INCOME DATA
Net Sales Rs m10,96824,530 44.7%  
Other income Rs m40437 9.1%   
Total revenues Rs m11,00724,967 44.1%   
Gross profit Rs m1,5653,268 47.9%  
Depreciation Rs m633623 101.6%   
Interest Rs m62664 9.4%   
Profit before tax Rs m9092,419 37.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139717 19.3%   
Profit after tax Rs m7711,701 45.3%  
Gross profit margin %14.313.3 107.1%  
Effective tax rate %15.329.7 51.4%   
Net profit margin %7.06.9 101.3%  
BALANCE SHEET DATA
Current assets Rs m5,7257,938 72.1%   
Current liabilities Rs m5,4547,743 70.4%   
Net working cap to sales %2.50.8 310.5%  
Current ratio x1.01.0 102.4%  
Inventory Days Days6275 82.6%  
Debtors Days Days726 1,176.8%  
Net fixed assets Rs m5,3079,377 56.6%   
Share capital Rs m1841,241 14.9%   
"Free" reserves Rs m6,3315,778 109.6%   
Net worth Rs m6,5167,897 82.5%   
Long term debt Rs m1,3232,322 57.0%   
Total assets Rs m11,97019,110 62.6%  
Interest coverage x15.64.6 336.9%   
Debt to equity ratio x0.20.3 69.1%  
Sales to assets ratio x0.91.3 71.4%   
Return on assets %7.012.4 56.2%  
Return on equity %11.821.5 54.9%  
Return on capital %12.430.2 41.1%  
Exports to sales %00-   
Imports to sales %057.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA14,186 0.0%   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,14114,268 8.0%   
Net fx Rs m3,366-14,268 -23.6%   
CASH FLOW
From Operations Rs m8862,441 36.3%  
From Investments Rs m-1,7061,103 -154.6%  
From Financial Activity Rs m1,316-3,426 -38.4%  
Net Cashflow Rs m497119 418.4%  

Share Holding

Indian Promoters % 59.2 52.5 112.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 4.6 271.7%  
FIIs % 6.0 4.8 125.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 38.2 58.6%  
Shareholders   12,805 130,070 9.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   RELIGARE ENT.  COMPACT DISC  NESCO LIMITED  INDIABULLS FIN. SER.  INGERSOLL RAND  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

FINOLEX IND. Announces Quarterly Results (1QFY19); Net Profit Up 29.5% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, FINOLEX IND. has posted a net profit of Rs 1 bn (up 29.5% YoY). Sales on the other hand came in at Rs 8 bn (up 0.4% YoY). Read on for a complete analysis of FINOLEX IND.'s quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Aug 21, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS